曲妥珠单抗联合化疗对人类表皮生长因子受体2阳性的局部晚期乳腺癌临床治疗

Clinical Treatment of Trastuzumab Combined with Chemotherapy on Human Epidermal Growth Factor Receptor 2 Positive Locally Advanced Breast Cancer

目的:探讨曲妥珠单抗联合化疗应用于人类表皮生长因子受体2(human epidermal growth factor receptor 2,HER-2)阳性的局部晚期乳腺癌(locally advanced breast cancer,LABC)的疗效。方法:随机将鄂州市中心医院2015年7月至2016年8月期间收治的HER-2阳性LABC患者76例分为对照组(n=38例)和观察组(n=38例),前者单纯应用化疗治疗,而后者则采用曲妥珠单抗与化疗的联合治疗方式,通过对比研究的方式,探讨不同治疗方案应用于HER-2阳性LABC患者的整体治疗效果。结果:观察组临床缓解率68.42%、控制率94.74%,均高于对照组(P<0.05);观察组获取二次手术的机会发生率84.62%明显高于对照组(P<0.05),其中观察组行乳房保留手术27.27%明显高于对照组(P<0.05);观察组肝功能损害、恶心呕吐的发生率明显低于对照组(P<0.05),观察组骨髓抑制Ⅲ-Ⅳ度发生率低于对照组(P<0.05),两组患者骨髓抑制Ⅰ-Ⅱ度发生率无明显差异(P>0.05)。结论:临床上针对HER-2阳性LABC患者应用曲妥珠单抗与化疗的联合治疗方式,可明显提升临床疗效,进一步改善患者生活质量。

Objective： To explore the clinical effects of trastuzumab combined with chemotherapy in application of HER-2 positive locally advanced breast cancer.Methods： 76 cases of patients with HER-2 positive LABC and who accepted treatments in our hospital from July 2015 to August 2016 were randomly divided into the control group （n=38 cases） and the observation group （n=38 cases）by the different treatment options. The former group was applied with the simple chemotherapy while the latter was given the treatment way of trastuzumab combined with chemotherapy. Then, the different treatment options for HER-2 positive LABC patients with the overall treatment effect were explored through a comparative study of the way.Results： The clinical remission rate in the observation group was 68.42%, and the control rate was 94.74%, which was higher than that of control group （P〈0.05）; the chance of getting two surgery in the observation group was 84.62%, which was significantly higher than that of the control group （P〈0.05）. And the breast conserving surgery in the observation group was 27.27%, which was significantly higher than that of the control group （P〈0.05）. The incidence of liver function damage and nausea and vomiting in the observation group were significantly lower than those of the control group （P〈0.05）. The incidence rate of bone marrow inhibitionⅢ-Ⅳ in the observation group was lower than that of control group （P〈0.05. There was no significant difference in the incidence of bone marrow suppressionⅠ-Ⅱ degree between the two groups （P〉0.05）.Conclusion： The application effect of trastuzumab combined with chemotherapy for patients with HER-2 positive LABC in the clinical, which can significantly improve the clinical efficacy, to further improve the quality of life of patients.